Navigation Links
Palatin Technologies Reports Positive Results for Phase 2B Bremelanotide Female Sexual Dysfunction Trial
Date:11/8/2012

CRANBURY, N.J., Nov. 8, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) today reported positive top-line results, including the successful achievement of statistical significance for the primary endpoint and key secondary endpoints in its Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for the treatment of female sexual dysfunction (FSD).

The data demonstrate that women taking bremelanotide showed statistically significant increases in the number of Satisfying Sexual Events (SSEs) and also showed statistically significant improved measures of overall sexual functioning and distress related to sexual dysfunction, compared with placebo.

The primary endpoint data analysis of 327 pre-menopausal women with female sexual arousal disorder (FSAD), hypoactive sexual desire disorder (HSDD), or a combination of both disorders, the most common types of FSD, shows a clinically meaningful and statistically significant improvement (p=0.018) in the number of SSEs in women taking bremelanotide doses (mean change from 1.6 at baseline increasing to 2.4; pooled 1.25 mg and 1.75 mg doses) versus placebo (mean change from 1.7 at baseline increasing to 1.9) over the study period, resulting in a 50% increase in SSEs with bremelanotide versus 12% with placebo.

"We are extremely pleased to report the successful completion of this trial, which achieved statistical significance in our primary endpoint and key secondary endpoints using independently developed and validated measurement tools. Importantly, we met the objectives of the trial which demonstrated excellent safety and efficacy of the drug and identified doses for advancement into Phase 3 trials and activities" stated Carl Spana, Ph.D., President and CEO of Palatin. "Our next steps are to continue to compile and analyze additional data, to start the preparation process for an end-of-Phase 2 meeting with the FDA, and to further our discussions with potential colla
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
2. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
3. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
4. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
5. Palatin Technologies, Inc. To Report Fiscal Year 2012 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2012
6. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on May 14, 2012
7. Palatin Technologies Announces Halting of Phase I Clinical Trial of Obesity Compound in AstraZeneca Research Collaboration
8. Palatin Technologies, Inc. Announces Pricing of $35 Million Private Placement of Common Stock and Warrants
9. Palatin Technologies, Inc. To Report Fiscal Year 2012 Fourth Quarter Results; Teleconference and Webcast to be held on September 11, 2012
10. Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
11. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/1/2014)... 2014  AtheroNova Inc. (OTCBB: AHRO), a biotech company ... safely regress atherosclerotic plaque and improve lipid profiles in ... offering of 4,000,000 shares of common stock, with each ... warrants to purchase one share of common stock.  The ... of $0.75 per share of common stock and $0.00001 ...
(Date:11/1/2014)... JOLLA, Calif. , Oct. 31, 2014 /PRNewswire/ ... human health technology and cell therapy company, today ... Ph.D., as Vice President of Global Technology Assessment and ... Global Solutions. The two will work together in ... business opportunities worldwide.   HLI,s Global ...
(Date:10/31/2014)... AMSTERDAM , October 31, 2014 ... the key barometer of future pharma industry health, analysis ... by UBM Live, celebrates the closing of its most ... than 36,000+ attendees and 2,500 exhibitors. Held this year ... senior-level decision makers and key players from 140+ countries ...
(Date:10/31/2014)... Caustic soda is utilized in the production of zeolites, sodium ... lead in the global caustic soda market, followed by the ... in the USA, Germany, Brazil and Canada, is currently the ... of output and production capacities. , The global caustic soda ... year in the years ahead. The APAC region is the ...
Breaking Biology Technology:AtheroNova Announces Closing of Public Offering of Common Stock and Warrants 2AtheroNova Announces Closing of Public Offering of Common Stock and Warrants 3Human Longevity, Inc. Hires Industry Experts Barry Merriman, Ph.D., and Paul Mola, M.S. to Lead New Global Solutions Initiative 2Human Longevity, Inc. Hires Industry Experts Barry Merriman, Ph.D., and Paul Mola, M.S. to Lead New Global Solutions Initiative 3CPhI Worldwide 2014 Announces Biggest Ever Show and Points to Pharma Growth in Brazil, Russia and Fast Emerging Africa 2CPhI Worldwide 2014 Announces Biggest Ever Show and Points to Pharma Growth in Brazil, Russia and Fast Emerging Africa 3CPhI Worldwide 2014 Announces Biggest Ever Show and Points to Pharma Growth in Brazil, Russia and Fast Emerging Africa 4CPhI Worldwide 2014 Announces Biggest Ever Show and Points to Pharma Growth in Brazil, Russia and Fast Emerging Africa 5CPhI Worldwide 2014 Announces Biggest Ever Show and Points to Pharma Growth in Brazil, Russia and Fast Emerging Africa 6China to Dominate Caustic Soda Market Through 2018, Says Merchant Research & Consulting in Its New Study 2
... , ... (NYSE: WX ), a,leading pharmaceutical, biotechnology, and ... and the United States,announced that it had been selected ... the fifth consecutive year. The list recognizes the 50,fastest-growing ...
... ... Advisory Committee on Climate Change (NACCC) through its Second National Communication (SNC) Project in ... preliminary climate change and sea level rise results that will form the background for ... , ...
... new generation of ultrasmall transistors and more powerful computer ... to reality after a key discovery by researchers at ... Los Angeles. The researchers have learned how to ... sharply defined at the atomic level, which is a ...
Cached Biology Technology:WuXi PharmaTech Named in Deloitte Technology Fast 50 China 2009 List for the Fifth Consecutive Year 2Preliminary Climate and Sea Level Changes for Vanuatu Through the Application of SimCLIM 2Preliminary Climate and Sea Level Changes for Vanuatu Through the Application of SimCLIM 3Preliminary Climate and Sea Level Changes for Vanuatu Through the Application of SimCLIM 4Nanowires key to future transistors, electronics 2Nanowires key to future transistors, electronics 3
(Date:10/30/2014)... help reduce or reverse soil subsidence and reduce ... Sacramento-San Joaquin River Delta by Dartmouth College researchers ... one of the first to continually measure the ... cycle through wetlands, appears in the journal by ... Worldwide, agricultural drainage of organic soils has resulted ...
(Date:10/30/2014)... Philadelphia, PA, October 30, 2014 – Bacteria in ... are critical for digestion. Yet, these same bacteria ... system if they penetrate the gut and enter ... natural response to protect the body, chronic or ... diseases. Prior research has established the involvement of ...
(Date:10/29/2014)... as a consequence of chemotherapy will benefit from a ... technology that prevents hair loss. , The research is ... scalp cooling manufacturing company, Paxman Coolers, of Fenay Bridge, ... University of Huddersfield. , The research will be led ... in the pharmacology of cancer treatment, which he will ...
Breaking Biology News(10 mins):Dartmouth study finds restoring wetlands can lessen soil sinkage, greenhouse gas emissions 2Breakdown in gut barriers to bacteria may promote inflammation and craving in alcoholics 2New technology on the way to aid cancer suffers who lose their hair after chemotherapy 2
... For thousands of years, bakers and brewers have relied ... Yet, University of Wisconsin-Madison researchers eager to harness this talent ... through sugars, these budding microbes can be picky eaters. ... the National Academy of Sciences , a Great Lakes Bioenergy ...
... tumors as parasites taking over their bodies, but this is ... cell biology professor at the University of California, Berkeley. ... a new species that, like most parasites, depends on its ... the detriment of its host. In a paper published ...
... farmers to plant on productive land with little snow ... concludes new research from Carnegie,s Julia Pongratz and Ken ... believe that regrowing forests on Northern lands that were ... global warming. But these studies did not consider the ...
Cached Biology News: Novel gene increases yeast's appetite for plant sugars 2Are cancers newly evolved species? 2Are cancers newly evolved species? 3Are cancers newly evolved species? 4Are cancers newly evolved species? 5Reforestation's cooling influence -- a result of farmer's past choices 2
... Blasticidin is a nucleoside ... It is a potent ... prokaryotic and eukaryotic cells. ... conferred by the products ...
... (Aph-1aL,S Loop 92-115), O2F1 Affinity Purified ... multiprotein complex consisting of presenilin, nicastrin, ... are necessary for full proteolytic activity. ... of a number of integral membrane ...
... a group of enzymes important in the ... The enzymes protect cells against toxicants by ... to electrophilic xenobiotics, and thereby defend cells ... of the compounds. GST activity is present ...
15(S)-HEDE is produced from 11Z,14Z-eicosadienoic acid by 15-LO. 15(S)-HEDE is an inhibitor of RBL-1 cell 5-LO with an IC50 value of 26 µM....
Biology Products: